<DOC>
	<DOCNO>NCT02829151</DOCNO>
	<brief_summary>- Prospective , randomize , control , multi-center study - A total 390 subject critical limb ischemia include accord inclusion exclusion criterion . - Patients randomize 1:1:1 manner triple antiplatelet therapy ( TAP : aspirin , clopidogrel , cilostazol ) group , dual antiplatelet therapy ( DAP : aspirin , clopidogrel ) A group , DAP ( aspirin , cilostazol ) B group . - All patient treat angioplasty critical limb ischemia . - Patients follow clinically 1 year procedure . - Ankle-brachial index Image study follow-up ( Duplex US CT angiography ) perform 1 year .</brief_summary>
	<brief_title>Comparison Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy Outcomes below-the Knee Endovascular Intervention Patients With Critical Limb Ischemia ( TAP CLI Study )</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients â‰¥ 19 year old Patients critical limb ischemia ( Rutherford 4 &amp; 5 ) Successful belowthe knee endovascular intervention . Major bleed event within recent 3 month high risk major bleed Patients require anticoagulation Allergic reaction antiplatelet drug Acute limb ischemia Severe hepatic dysfunction ( 3 time normal reference value ) Pregnant woman woman potential childbearing Life expectancy &lt; 1 year due comorbidity Previous amputation target limb</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Peripheral artery disease</keyword>
	<keyword>Critical limb ischemia</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Antiplatelet therapy</keyword>
</DOC>